Vital Therapies (VTL) Stock Price, News & Analysis

Company Overview

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Key Stats

• Today's Range: $0.93 to $0.96
• 50-Day Range: $0.83 to $14.50
• 52-Week Range: $0.15 to $9.75
• Volume: 1.10 million shs
• Average Volume: 21.62 million shs
• Market Capitalization: $40.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VTL Stock Analysis - Frequently Asked Questions

How were Vital Therapies' earnings last quarter?

Vital Therapies, Inc. (NASDAQ:VTL) posted its earnings results on Tuesday, August, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03.

What other stocks do shareholders of Vital Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vital Therapies investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Anthera Pharmaceuticals (ANTH), Bristol Myers Squibb (BMY), Novavax (NVAX) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 8/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VTL
• CIK: 1280776
• Web: vitaltherapies.com
• Phone: (858) 673-6840
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -235.33%
• Return on Assets: -182.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.97
• Quick Ratio: 6.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 42,370,000
• Free Float: N/A
• Market Cap: $40.25 million
• Optionable: Not Optionable
• Beta: 3.51